卓定康錠 0.75 毫克

Valsts: Taivāna

Valoda: ķīniešu

Klimata pārmaiņas: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Aktīvā sastāvdaļa:

EVEROLIMUS

Pieejams no:

台灣諾華股份有限公司 台北市中山區民生東路三段2號8樓 (01516589)

ATĶ kods:

L04AA18

Zāļu forma:

錠劑

Kompozīcija:

EVEROLIMUS (9200099400) MG

Vienības iepakojumā:

鋁箔盒裝

Klase:

製　劑

Receptes veids:

須由醫師處方使用

Ražojis:

NOVARTIS PHARMACEUTICAL MANUFACTURING LLC KOLODVORSKA, 27, 1234 MENGES, SLOVENIA SI

Ārstniecības joma:

everolimus

Ārstēšanas norādes:

腎臟及心臟移植併用減量ciclosporin微乳製劑及類固醇，預防腎臟或心臟移植的成人病患之免疫器官排次作用。肝臟移植用於預防肝臟移植病患之器官排斥。Certican應於接受移植手術至少30天後與減量的tacrolimus及類固醇併用。

Produktu pārskats:

有效日期: 2028/01/24; 英文品名: Certican 0.75mg tablets

Autorizācija datums:

2008-01-24

Lietošanas instrukcija

ಢԙᇄᏘ࠮
ᒻᏘѴᢎ࣏ҩՓՍష༁ՓȂڎσ౩ү઴Ȃ༫ל֤ࡵҁఇ७᜞ጢȄ
кԙϷ
ڟۡஶᒻؐᒻ֤Ԥ
0.25mg
ȃ
0.5mg
ܖ
0.75mg everolimus
Ȅ
፭לᏘ
Butylated hydroxytoluene (E321)
Ȃ
magnesium stearate
Ȃ
lactose monohydrate
Ȃ
hypromellose
Ȃ
crospovidone
Ȃ
lactose anhydrous
Ȅ
ᎌᔖ੿Ȉ
๫᠚ЅЖ᠚ಋේ
ځҢ෵໔
ciclosporin
ཌٰᇧᏘЅ᜸ھ᎕ȂႱ٩๫᠚ܖЖ᠚ಋේޟԙΡ੾ΡϞ
ջ࣫Ꮲۢ௶ҌհҢȄ
م᠚ಋේ
ҢܻႱ٩م᠚ಋේ੾ΡϞᏢۢ௶ҌȄ
Certican
ᔖܻ௥ڧಋේЙ೚ՍЍ
30
Јࡣ
ᇄ෵໔ޟ
tacrolimus
Ѕ᜸ھ᎕ځҢȄ
ҢݲҢ໔Ȉ
໠ۖЅᆰࡻо
Certican
ݽᕛѫџҥڎԤᏢۢಋේࡣջ࣫׻ڙݽᕛငᡛޟᚂৱ
ஈ՗Ȃиџுڗ
everolimus
ޟӒՖᅿก঄Ȅ
Ꮨ໔
ΙૡҬ኿ఊတ
ԙΡȈ
๫᠚ЅЖ᠚ಋේ
࡚ដ๫᠚ܖЖ᠚ಋේޟ੾ΡߑۖᏘ໔࣏
0.75
యպΙЈΠԩȂܻಋේࡣᔖᅾ
פ݈ҢȄ
م᠚ಋේ
ܻಋේՍЍ
30
Јࡣ໠݈ۖҢ
Certican
Ȅ࡚ដم᠚ಋේޟ੾ΡߑۖᏘ໔࣏ο݈
1.0
యպΙЈΠԩ
(
ؐЈ
2.0
యպ
)
ȂځҢ෵໔ޟ
tacrolimus (
୤ࣼɆݽᕛ᛾ސ
ᅿกɇϞɆܻم᠚ಋේ੾Ρ
tacrolimus
ޟ࡚ដᏘ໔ɇണ࿽
)
Ȅ࡚ដᅿก੾Ρ
ޟ
everolimus
Ѕ
tacrolimus
Ֆϛᐨ࡙Ȅ
᜸ھ᎕ޟᏘ໔џٷএտ੾ΡޟᖝחޑݷЅಋේᏢۢޟђ૖پ෵໔Ȅ
፡ᐌ
Certican
Ꮨ໔оᆰࡻശճՖϛᐨ࡙
(C
0
)
ӵ
3-8 ng/ml
Ȅ
੫੆ఊတ
༃Ρ੾ΡȈ
ࣀಢᙑᔮࢥᜌᄂ༃Ρ੾Ρޟ๫᠚ಋේีҡࡨܒ௶ҌޟٱӇȂڏีҡ౥݂ᡗၶ
ᇄߨ༃ΡఊတଽȄԤ३ޟၥਟᡗҰ༃Ρ੾Ρџ૖໸ၶଽޟ
Certican
Ꮨ໔Ȃо
ႀڗԃߨ༃ΡఊတܻԙΡ࡚ដᏘ໔ήࣺխޟᕛਝ
(
୤ࣼɆ᛾ਝᏰȂ᛾ސଢ଼Ψ
ᏰɇΙ࿽
)
ȄҬࠉᕛਝᇄԊӒܒኵᐃࣱΪϷԤ३Մฒݲବᄇ
everolim
us
ٺҢ
ܻ༃Ρ੾Ρඪю࡚ដȄ
ڟۡஶ
ᒻ
!
0.25
యպ!
⠡⇨♑Ⱚ઎Ὦ
024770
⚦
0.5
యպ!
⠡⇨♑Ⱚ઎Ὦ
024772
⚦
0.75
యպ!
⠡⇨♑Ⱚ઎Ὦ
024771
⚦
CERTICAN
Tablets
0.25 mg
0.5 mg
0.75 mg
ҏ᛾໸ҥᚂৱ೎ПٺҢ
ᒵᐅܒջ࣫׻ڙᏘ
ٺҢܻڋ็
(
ωܻ
18
ྑ
)
Ȉ
ฒٗஊޟၥਟپЛࡻ
Certican
ٺҢܻڋ็ᇄߧЍԑ٘ΰȄծ࢐ȂϐԤЍኵٺ
Ңܻ๫ಋේޟ